IDEAYA Q1 2025 net loss $72.2M; cash ~$1.05B funds ops into 2029; darovasertib enrollment >300 pts

IDEAYA Biosciences, Inc.

2025-Q1 EPS reported -$0.82

Cash, equivalents and securities $1.05B as of March 31, 2025, supporting updated runway into 2029.
Net loss of $72.2M in Q1 2025; R&D expenses $70.9M (down from $140.2M Q4 2024 incl. one-time $75M license payment).
Over 300 patients enrolled in darovasertib + crizotinib 1L MUM registrational trial; median PFS readout targeted by YE 2025.
FDA Breakthrough Therapy designation for neoadjuvant darovasertib in primary UM; Phase 3 design finalized after Type D meeting.
Three IND filings targeted in 2025: PRMT5 (IDE892), B7H3/PTK7 ADC (IDE034), KAT6/7 (IDE574); IDE849 Phase 1 started in US.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.